Daiichi's Phase III Quizartinib Data Pave Way In Niche AML Market
Executive Summary
Showing an overall survival improvement in the especially hard to treat FLT3-ITD mutated patients is a significant achievement in AML, analysts say.
You may also be interested in...
Keeping Track: Industry Channels Inner Gottlieb As Commissioner Departs US FDA
The latest drug development news and highlights from our US FDA Performance Tracker.
AML Paradigm Shift: Doctors Welcome Many New Approvals And Approaches
This year's ASH meeting reflected a peak of development success, with many new approvals and many more in the pipeline.
ASH Preview: Practice-Changing Darzalex And Imbruvica, Advances In Beta-Thalassemia And More
Late-breaker presentations for Darzalex in multiple myeloma and Imbruvica in CLL will showcase "practice-changing" results in front-line settings. Other highlights include new treatments for beta-thalassemia, such as Acceleron's and Celgene's luspatercept.